Lineage Cell Therapeutics (LCTX) EBT Growth (3y) (2013 - 2026)

Lineage Cell Therapeutics (LCTX) EBT Growth (3y) (2013 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBT Growth (3y) (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 9.34%
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 40.43%
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 12.01%
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -1.05%
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 86.16%
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Lineage Cell Therapeutics 267.08 Mn 203.18 Mn 1.73 Mn -46.03%

Historic Data

Download Data
DateValue
Mar 31, 2026 -46.03%
Dec 31, 2025 2.92%
Sep 30, 2025 -50.08%
Jun 30, 2025 -49.22%
Mar 31, 2025 1.35%
Dec 31, 2024 51.23%
Sep 30, 2024 30.26%
Jun 30, 2024 -5.15%
Mar 31, 2024 -65.45%
Dec 31, 2023 -89.37%
Sep 30, 2023 3.44%
Jun 30, 2023 7.29%
Mar 31, 2023 9.69%
Dec 31, 2022 -6.01%
Sep 30, 2022 31.71%
Jun 30, 2022 39.94%
Mar 31, 2022 -30.12%
Dec 31, 2021 14.83%
Sep 30, 2021 -28.72%
Jun 30, 2021 -2.24%